- Home
- HERZ vs KYNB Comparison
HERZ vs KYNB Comparison
Compare HERZ & KYNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HERZ | KYNB |
|---|---|---|
| Founded | N/A | 1993 |
| Country | United States | United States |
| Employees | N/A | 34 |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.7M | 27.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | HERZ | KYNB |
|---|---|---|
| Price | $16.01 | $6.82 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 12.3K | ★ 31.1K |
| Earning Date | N/A | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $0.15 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.62 | $6.32 |
| 52 Week High | $19.30 | $9.58 |
Technical Indicators
Market Signals| Indicator | HERZ | KYNB |
|---|---|---|
| Relative Strength Index (RSI) | 40.09 | 48.40 |
| Support Level | $15.27 | $6.58 |
| Resistance Level | $16.39 | $7.41 |
| Average True Range (ATR) | 0.66 | 0.31 |
| MACD | -0.13 | 0.01 |
| Stochastic Oscillator | 12.66 | 20.36 |
Price Performance
Historical ComparisonAbout HERZ Herzfeld Credit Income Fund Inc.
Herzfeld Credit Income Fund Inc is a non-diversified, closed-end management investment company. Its primary investment objective is to maximize risk-adjusted total returns, and its secondary investment objective is to generate high current income.
About KYNB Kyntra Bio Inc. Common Stock
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.